ANIX Gets New Patent for Breast Cancer Vaccine Technology, Stock Up

Core Viewpoint - Anixa Biosciences (ANIX) shares rose by 13% following the announcement of a new patent for its breast cancer vaccine technology, developed in collaboration with Cleveland Clinic, which is currently in early-stage studies [1][4]. Group 1: Patent and Technology - The new patent broadens the immunogenic compositions for Anixa's breast cancer vaccine, focusing on the human α-lactalbumin protein, which is present in breast tissue during lactation and expressed in certain breast cancers, making it a viable target for immunoprevention [2]. - The patent enhances Anixa's intellectual property portfolio, emphasizing the uniqueness of its investigational breast cancer vaccine, thereby strengthening the company's competitive position [4]. Group 2: Clinical Trials and Future Plans - The ongoing phase I study is assessing the breast cancer vaccine's maximum tolerated dose and immune response in patients with early-stage, triple-negative breast cancer, showing antigen-specific immune responses and a favorable safety profile [5]. - Based on positive findings, Anixa plans to initiate a phase II study in 2025 to evaluate the vaccine's therapeutic effect in a pre-surgery setting for breast cancer [5]. Group 3: Collaborations and Other Developments - Anixa is collaborating with Cleveland Clinic on additional vaccines targeting ovarian, lung, colon, and prostate cancers, which are currently in pre-clinical or discovery stages [7]. - The innovative vaccine technologies have a unique mechanism of action, potentially offering therapeutic benefits over existing treatments, with Cleveland Clinic entitled to royalties from their development [8]. - Anixa is also developing an immunotherapy candidate for ovarian cancer in partnership with Moffitt Cancer Center, currently in a phase I study [9].